ASCO 2023 | Antibody-drug conjugates in the treatment of solid tumors

Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses the use of antibody-drug conjugates (ADCs) in the treatment of solid tumors. The tumor agnostic Phase II DESTINY-PanTumor-02 (NCT04482309) trial investigated trastuzumab deruxtecan (T-DXd) in patients with gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma with HER-2 expression. Tumor agnostic approaches are possible with ADCs and have shown high response rates. Another trial, the Phase I/II TROPION-PanTumor02 (NCT05460273) study, is investigating the use of a bispecific ADC and has demonstrated impressive response rates for lung cancer and other malignancies. Finally, Dr Shitara, highlights the transmembrane protein, CDCP1, as a new target for small cell lung cancer (SCLC) due to tumor-specific expression. This data is encouraging for the use of ADCs in the treatment of a variety of cancers. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.